Soleus Adds a Significant Number of Celcuity Shares

Soleus Capital increased its Celcuity (NASDAQ: CELC) position by 629,398 shares to hold over 1.8 million shares worth roughly $180.4 million, making CELC 6.7% of the fund’s AUM and its third-largest holding in the reported 13F. Celcuity, a clinical‑stage biotech with no current revenue, had a market close price of $104.23 (Feb. 11, 2026) and a market cap of $4.85 billion, with TTM net loss of $162.7 million; the shares have risen about 745% over the past year. The transaction signals institutional bullishness but the company remains high‑risk, dependent on drug approvals and future commercialization for revenue.

Analysis

Market structure: Soleus’s large buy (now 6.7% of its AUM) is a concentrated, stamp-of-conviction trade that likely reinforces retail/momentum flows into CELC and lifts implied volatility; primary beneficiaries are CELC equity holders and options sellers collecting premia, while small-cap clinical peers may face rotational outflows. With CELC at $104 (mkt cap $4.85bn) and no revenue, pricing power is purely sentiment-driven — any positive Gedatolisib/CELsignia readout can spark >50% moves; conversely, failure would compress multiples sharply.

Risk assessment: Tail risks include a negative Phase readout or FDA setback (40–70% downside), rapid dilution from a financing round that could halve per‑share value, or a large fund exit triggering liquidity stress within days. Near-term (days–weeks) price action will be volatility-driven; medium-term (3–12 months) hinges on trial milestones and cash runway; long-term (12–36 months) depends on commercialization/licensing success and diagnostic adoption.

Trade implications: Direct plays should size positions small (1–3% of capital) and favor option-defined risk: buy 9–12 month call spreads or long stock with protective puts; pair trades (long NVCR or KRYS, short CELC) exploit binary risk asymmetry — target 2:1 notional bias in favor of the revenue-generating name. Sector tilt: reduce uncapped biotech long exposure by ~25% and shift into device/recurring-revenue oncology (e.g., NVCR) for 3–12 month stability.

Contrarian angles: Consensus elevates CELC on momentum but underestimates dilution and companion-diagnostic commercialization hurdles; buying here without defined downside protection is likely overdone. Historical parallels: biotech moonshots post-conviction buys often retrace >30% on secondary offerings; therefore, value exists only on >25–35% pullbacks or after demonstrable non-dilutive partnership announcements.

Key Decisions for Investors

• Establish a tactical long in CELC equal to 1% of portfolio risk capital only if paired with downside protection: buy shares or 9–12 month call spread and simultaneously buy a 9–12 month $65–$75 put (≈35–45% OTM) to cap loss; increase to 2–3% only after positive clinical/regulatory catalyst within 6–12 months.
• Execute a relative-value pair: go long NVCR (2% portfolio) and short CELC (1.5% portfolio) equalizing dollar exposure to exploit revenue stability vs binary trial risk; target exit when NVCR outperforms CELC by +20% or CELC declines >30, timeframe 3–12 months.
• Use a collar if buying CELC outright: buy CELC, buy 12‑month $70 put and sell 12‑month $150 call to reduce net cost and limit downside; implement only if entry price is <$110 and maintain position size ≤2% of capital.
• Do not add to CELC position if the company announces a non‑partnered equity financing or insider sell that increases float >5% within 90 days; reduce exposure by 50% on such a dilution trigger and re-evaluate after 30 days.
• Monitor near-term catalysts: track Gedatolisib enrollment milestones, any FDA Type A/B meetings, and cash runway metrics (company must show ≥12 months runway or partnership letters within 90 days) — if unmet, shift remaining exposure into NVCR/KRYS within 30 days.